July 2015 Newsletter

July 16, 2015:

Glaukos Raises $118 Million in Successful IPO

The stock price soared to $31.22 by the end of the first day of trading.

July 16, 2015:

Expanding PC-IOL Options Expected to Fuel Demand Among Patients

Nearly 11 percent growth is forecast for presbyopia-correcting lenses globally in 2015 and 2016.

July 16, 2015:

Allergan CEO Saunders Discusses Plans for Irvine, CA, Campus

He calls the former headquarters the largest and most important site in the new Allergan’s system.

July 16, 2015:

Robert Ford is Leading Abbott Medical Optics on Interim Basis

Ford was appointed executive vice president of medical devices in June.

July 16, 2015:

Calhoun Vision Boosts Management Team

Ron Kurtz, MD, and Eric Weinberg add wealth of ophthalmic experience.

July 16, 2015:

Global Demand for Refractive Surgery Growing, Despite Declines in Some Key Markets

Procedure volume is expected to increase at a compounded annual rate of 3.4 percent over the next five years.

July 16, 2015:

Rising Global Demand for Phaco and Femtosecond Surgery to Fuel Cataract Equipment Market

An estimated 15.5 million ultrasonic phaco procedures will be performed worldwide in 2015.

July 16, 2015:

US House Passes 21st Century Cures Act; Senate Version is Moving More Slowly

White House takes issue with some proposals, including marketing of off-label uses of products.

July 16, 2015:

Health Insurer Mergers Will Reduce Pricing Power of Drug Makers, Moody’s Says

Consolidation activity accelerated after the Supreme Court’s ruling in favor of health care subsidies.

July 16, 2015:

Avalanche Reports Phase IIa Results for Wet AMD Gene Therapy; Regeneron Faces Deadline on Option

The stock market’s reaction to the news may have oversimplified the study’s results.

July 16, 2015:

CMS Seeks Feedback on In-Office Cataract Surgery

The agency says advancements in technology have significantly reduced operating time and improved safety and patient outcomes.

July 16, 2015:

Santen Files IND for Novel Agent that May Combat Anti-VEGF Resistance

DE-122 is an anti-endoglin antibody first developed for cancer treatment.

July 16, 2015:

IBMD Developing Precision Capsulotomy System; Mark Packer, MD, Joins Team

The ApertureRx appears to be pointed toward the same lower cost market as the Zepto capsulotomy system.

July 16, 2015:

Pioneer Robert M. Sinskey, MD, Dies at Age 90

Sinskey was an early adopter of phacoemulsification in 1972 and played an important role in development and acceptance of the procedure.

July 16, 2015:

July 2015 New Briefs

Social media